PVCT - Provectus Biopharmaceuticals Inc. (PVCT) Q1 2024 Earnings Call Transcript

2024-02-22 18:56:04 ET

Provectus Biopharmaceuticals, Inc. (PVCT)

Q1 2024 Earnings Conference Call

February 22, 2024 3:00 PM ET

Company Participants

Alyssa Barry – irLabs Investor Relations

Nathan Kibler – Outside Legal Counsel-Baker Donelson

Ed Pershing – Chairman

Dominic Rodrigues – Board Vice Chairman

Conference Call Participants

Presentation

Operator

Thank you for standing by. This is the conference operator. Welcome to the Provectus Biopharmaceuticals First Quarter 2024 Conference Call. As a reminder, all participants are in listen-only mode and the conference is being recorded.

I would now like to turn the conference over to Alyssa Barry, irLabs Investor Relations. Please go ahead.

Alyssa Barry

Thank you, operator. Good afternoon. Welcome to the first quarter 2024 conference call of Provectus Biopharmaceuticals, which is developing immunotherapy medicines for cancer and other diseases. My name is Alyssa Barry, Co-Founder and Principal of investor relations firm irLabs. I am hosting today’s call. Ed Pershing, Chairman of Provectus’ Board of Directors, and Dominic Rodrigues, Board Vice Chairman, will provide company updates and their remarks.

First, Nathan Kibler, Provectus’ Outside Legal Counsel from the law firm of Baker Donelson, will read the company’s forward-looking statements....

For further details see: